HeartBeam Aims to Close Critical Gap in Early Cardiac Detection with Cable-Free 12-Lead ECG

HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising clinical need and evolving innovation. One of the most persistent challenges in cardiac care is pre-hospital delay, with many patients not seeking medical attention at the onset of symptoms. Traditional electrocardiogram testing is typically conducted in clinical environments, which may not coincide with the onset of symptoms such as intermittent chest pain, palpitations or other warning signs. As a result, patients often defer care and clinicians are left without the data needed to make timely, informed decisions.

HeartBeam is working to address this gap by transforming how ECG data are collected and used. The company's HeartBeam System is designed as a cable-free, high-fidelity ECG platform capable of capturing the heart's electrical signals from three distinct directions for arrhythmia assessment. By collecting multidirectional signals, the system is intended to provide a more comprehensive representation of cardiac activity compared with conventional single-lead devices. The HeartBeam System uses a compact, credit-card size, portable design with embedded electrodes that allow patients to record ECG signals without adhesive patches or wires. This simplifies the user experience while maintaining the quality of data needed for clinical interpretation.

The system's ability to generate synthesized 12-lead ECG signals from these recordings is particularly significant, as it brings clinical-grade data traditionally associated with hospital-based equipment into a portable format. The HeartBeam System is currently FDA cleared for arrhythmia assessment and the company plans to submit for an indication expansion for heart attack detection in the future. This expansion could further close the critical gap in early cardiac detection, potentially reducing the time to diagnosis and treatment for acute coronary syndromes.

HeartBeam holds 13 U.S. and 4 international-issued patents related to technology enablement, underscoring its commitment to innovation in cardiac care. The company's platform technology is designed to be used in portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care, all outside of a medical facility, thus redefining the future of cardiac health management.

For more information on the technology and its implications, the full article is available at https://ibn.fm/X6IEc. Additional updates on HeartBeam can be found in the company's newsroom at https://ibn.fm/BEAT.